Posts Tagged ‘chemotherapy’

The 70-Gene Signature as an Aid to Treatment Decisions in Early Breast Cancer

Posted by • August 24th, 2016

“Your cancer has been successfully removed with surgery, but there may be a role for chemotherapy to protect you in the future.” This message is expressed by oncologists in consulting rooms all over the world. In women with early-stage breast cancer, adjuvant chemotherapy may be offered as an insurance policy against cancer recurrence. Risk of… Read More…

Risks for Second Cancer After Hodgkin’s Lymphoma Therapy

Posted by • December 23rd, 2015

You are meeting Mrs. Mason in your primary care clinic for the first time today. She has a history of Hodgkin’s lymphoma and was treated with chemotherapy and radiation therapy over 25 years ago. You wonder what is her risk for additional cancers as a result of treatment for Hodgkin’s lymphoma? While the use of radiation… Read More…

Prospective Validation of a 21-Gene Expression Assay (OncotypeDX) in Breast Cancer

Posted by • November 18th, 2015

Imagine it is 1970. You are a 50-something year old woman and your doctor has just palpated a 1 cm mass in your left breast.  What are your options for treatment?  Unfortunately, radical mastectomy, introduced by Dr. William Halsted in 1894, remained the standard of care at that time.  Breast cancer treatment as it was… Read More…

Prophylaxis against Venous Thromboembolism in Ambulatory Cancer Patients

Posted by • June 27th, 2014

Patients with cancer are at increased risk for thrombosis, and those with thrombi have poorer overall survival rates than those without. In a new review article, Dr. Jean Connors from Brigham and Women’s Hospital and Dana Farber Cancer Institute summarizes available data and provides guidance for determining which patients might benefit from thromboprophylaxis. The incidence of… Read More…

Circulating Tumor DNA

Posted by • March 27th, 2013

Fifty years ago, oncologists relied upon the clinical exam to follow breast cancer patients with metastatic disease. Patients were treated with chemotherapy, and then the physicians waited for symptoms to return before deciding on the next treatment course. Some patients could go months or even years without symptoms, but during this time they played a… Read More…

Brain Mass

Posted by • May 31st, 2012

In this week’s Case Record of the Massachusetts General Hospital, a 54-year-old man had transient then persistent partial loss of vision. Images of the brain showed two adjacent masses in the left occipital and posterior parietal regions. A diagnostic procedure was performed. Glioblastoma is a highly malignant tumor, with a median survival of 9 to 14 months… Read More…

Breast Cancer

Posted by • October 5th, 2011

In a study from Slamon et al., trastuzumab added to a nonanthracycline regimen to treat HER2-positive breast cancer resulted in rates of disease-free and overall survival that were similar to those for an anthracycline-containing regimen, with lower rates of cardiac toxicity and secondary leukemia. The HER2 gene encodes a tyrosine kinase receptor that mediates critical signaling… Read More…

Metastatic Pancreatic Cancer

Posted by • May 13th, 2011

In a new study from Conroy et al., a four-drug combination chemotherapy regimen was associated with objective responses in more than 30% of patients and increased survival by more than 4 months, as compared with standard gemcitabine. Pancreatic adenocarcinoma was the fourth leading cause of death from cancer in the United States in 2010, and it… Read More…

Nanomedicine

Posted by • December 17th, 2010

The latest article in our Current Concepts review series, “Nanomedicine,” comes from Drs. Betty Kim, James Rutka, and Warren Chan of the University of Toronto. The field of nanomedicine aims to apply nanotechnology to the diagnosis and treatment of diseases at the molecular level. Clinical Pearls • What do nanomaterials consist of? Nanomaterials generally consist of metal atoms,… Read More…